Dr Alex Alderton | Head of Cellular Operations

Alderton, Alex

Alex is the Head of Cellular Operations at the Wellcome Sanger Institute. In this role she leads a team of 55 scientists covering a broad range of scientific areas including flow cytometry, CRISPR genome editing, stem cells, high content imaging and organoid derivation. Collectively, the team provide cell biology expertise to help deliver some of the institutes largest and most ambitious projects.

Alex has a background in cell and molecular biology, in particular the development of cell lines and assays for large scale or high throughput science. She completed a Post doc on prion-based neurological disorders at the University of Bath in 2006 before joining Pfizer to work in cell line and assay development for a variety of early stage drug discovery projects. In 2012, Alex move to the Sanger to take up a senior role in the newly formed Cellular Generation and Phenotyping (CGaP) core facility, where she went onto become the facility head in 2015. In 2017, Alex moved into her current role as Head of Cellular Operations.

Alderton, Alex
Alex's Timeline
2017

Head of Cellular Operations at the Sanger Institute

2015

Head of Cellular Generation and Phenotyping at the Sanger Institute

2012

Senior Scientific Manager at the Sanger Institute

2009

Principal Scientist, Research Enabling Group at Pfizer

2007

Senior Scientist, Primary Pharmacology Group at Pfizer

2006

Screening Scientist, Primary Pharmacology Group at Pfizer

2004

Post Doc at University of Bath

2000

PhD in Molecular Biology, University of Kent